No Data
No Data
Express News | NanoViricides Inc: NV-387 Treatment Resulted in Significant Reduction in Mucus Load in Lungs
Express News | NanoViricides Inc: NV-387 Treatment Significantly Protected Lungs of Balb-C Mice Lethally Infected With Influenza a/H3N2 Virus
Express News | NanoViricides Inc: NV-387 Treatment Resulted in Significant Reduction in Lung Infiltration and Lung Cell Death
Express News | NanoViricides Inc: Ultra-Broad-Spectrum Antiviral NV-387, Clinical Phase II Stage Drug Candidate, Was Found Effective in Protecting Lungs From Damage
Express News | Nanoviricides Reports That The Ultra-broad-spectrum Antiviral NV-387, A Phase 2 Stage Drug Candidate, Was Found To Be Effective In Protecting Lungs From Damage In A Lethally Infected Influenza H3N2 Mouse Model
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs From Damage in Lethally Infected Animal Model
SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and global leader in broad-spectrum antiviral nanomedicines, reports that
103216711 : is this a good stock for the long term?
TrytosaveabitOP 103216711: I don’t have enough DD done on it to answer that honestly! GL